Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Quest Diagnostics (NYSE: DGX) declared a quarterly cash dividend of $0.86 per share, payable on January 27, 2027.
The dividend will be paid to shareholders of record of Quest Diagnostics common stock on January 12, 2027.
Quest Diagnostics (NYSE: DGX) will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on December 1, 2026.
Chief Financial Officer Sam Samad will speak in Miami at 2:10 p.m. Eastern Time. The chat and Q&A will be webcast live at ir.QuestDiagnostics.com. An archive will be available within 24 hours after the live event concludes and remain available until December 15, 2026.
Quest Diagnostics (NYSE: DGX) will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026. Executive Vice President and Chief Financial Officer Sam Samad will join a fireside chat at 8:30 a.m. Eastern Time. The chat and Q&A will stream live at ir.QuestDiagnostics.com. An archived webcast will be available within 24 hours after the event concludes and remain available until December 1, 2026.
Quest Diagnostics (DGX) reported third-quarter 2026 revenue of $3.10 billion and raised its full-year revenue and earnings outlook. Revenue rose 10.0% year over year. Reported diluted earnings per share increased 28.7% to $2.78, while adjusted diluted earnings per share rose 15.4% to $3.00. Operating margin reached 15.5%, versus 13.7% a year earlier.
Test-order volume grew 14.5%, but revenue per order fell 4.2%. Operating cash flow increased 8.8% to $611 million. Quest now expects 2026 revenue of $12.065 billion–$12.105 billion, reported diluted earnings per share of $10.21–$10.31 and adjusted diluted earnings per share of $11.25–$11.35. Expected annual operating cash flow rose to approximately $1.90 billion. Quest also signed a definitive agreement to acquire select outreach lab assets from a Northeastern U.S. health system.
Quest Diagnostics (DGX) and Waters Corporation (WAT) announced a collaboration to expand at-home cervical cancer screening access beginning in 2027. Quest plans to offer Waters' FDA-cleared Onclarity Self-Collection Kit through its clinician network, health-plan Gaps in Care channel and consumer testing site, questhealth.com, alongside its patient service centers.
Patients will collect samples at home and return them to Quest by mail or through approximately 2,000 patient service centers nationwide. Quest will process the samples using the BD COR System and the FDA-approved BD Onclarity HPV Assay, which detects human papillomavirus and provides results distinguishing several virus types. The companies intend the collaboration to broaden access for patients who face barriers to traditional screening.
Quest Diagnostics (DGX) researchers coauthored a study suggesting broader screening criteria could double detection of primary aldosteronism, a hormonal cause of hypertension.
Published in Hypertension, the retrospective study used Quest laboratory results from over 60,449 U.S. patients. Broader criteria identified 26.2% as positive, versus 13.0% under the 2025 Endocrine Society criteria. The broader criteria lowered the aldosterone threshold and removed the aldosterone-to-renin ratio requirement. Additional patients identified also showed clinical conditions consistent with the disorder, based on insurance billing records. The findings suggest potential for earlier detection, but limitations include lack of confirmatory testing and the retrospective design.
Quest Diagnostics (DGX) reported study results showing its Haystack MRD blood test predicted colorectal cancer recurrence with 100% specificity in the evaluated cohort. Published in The Journal of Molecular Diagnostics, the study retrospectively tested residual specimens from patients in the DYNAMIC and DYNAMIC-III trials of stage II and III colorectal cancer. The test detects circulating tumor DNA, fragments of tumor genetic material in blood, to identify residual or recurrent disease.
Sensitivity was 100% at three years and 83.3% at five years, with 100% specificity at both follow-ups, meaning no false-positive results in the cohort. In a separate comparison at median follow-up of 60 months, recurrence-detection sensitivity was 88.9%, versus 11.1% for the standard blood marker CEA. Analytical performance was validated across 23 solid tumor types; an Early Experience clinical cohort showed tumor DNA detection across 27 types.
Quest Diagnostics (DGX) will release its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens. A conference call to discuss the results will begin at 8:30 a.m. Eastern Time and will be accessible by phone and live webcast via the company’s investor relations website.
Quest Diagnostics (DGX) reported results of a large JAMA Network Open study showing that U.S. patients with antibodies to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more than four times as likely to have antibodies to other tick-borne pathogens as those without Lyme antibodies.
The analysis covered de-identified results from 193,260 individuals tested between January 2021 and December 2025, and found that 29.5% of Lyme-seropositive patients were co-seropositive for at least one additional tick-borne pathogen, versus 5.5% among Lyme-seronegative patients. Overall seropositivity rates in the cohort were 5.0% for B. burgdorferi, 3.4% for Babesia microti, 3.1% for Anaplasma phagocytophilum, and 1.0% for Ehrlichia species. Co-seropositivity was highest in the Northeast, where 31.1% of Lyme-seropositive patients had antibodies to at least one other pathogen, and Babesia antibodies reached 18.5%. The study used national real‑world serology data and the company highlights that results may reflect past exposure rather than active infection.
Quest Diagnostics (DGX) released results of a national survey of 1,024 registered voters showing broad concern that scheduled Medicare lab payment cuts could reduce patient access to diagnostic testing starting January 1, 2027.
The survey found 96% of voters view diagnostic lab tests as important to their or their family's care, 75% call them “very important,” and 83% relied on a lab test in the past two years to guide a medical decision. Under the Protecting Access to Medicare Act (PAMA), data from under 1% of labs helped set Clinical Lab Fee Schedule (CLFS) rates, cutting nearly $4 billion from 2018–2020, with further CLFS cuts of up to 15% annually scheduled for 2027–2029 without new legislation.
Among respondents, 88% would have concerns if Medicare lab rates were set too low, 93% are likely to support candidates who protect access, and around three-quarters across party lines say Congress should act now. Quest and the American Clinical Laboratory Association are urging passage of the bipartisan RESULTS Act, backed by about 130 congressional sponsors and more than 70 medical and patient groups, to stabilize Medicare lab payment rates.